Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effectRead Article
This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. TheRead Article
A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.Read Article
A review of available data fails to show an increased risk of melanoma in IMID (inflammatory bowel disease, rheumatoid arthritis, and psoriasis) patients treated with systemic biologic therapies.
There have been sporadic uncontrolled observational reports suggesting a link betweenRead Article
Patients with autoimmune diseases who were treated with tumor necrosis factor (TNF) inhibitors had an increased risk of developing inflammatory central nervous system (CNS) adverse events, a nested case-control study found.Read Article
This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr. Nash presents the impact of COVID inRead Article
Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs. 56% ;p=0·009) and greater improvements in CRP and pulmonary function (72% vs 50%) comparedRead Article
BCG & COVID: 1) Israeli study shows BCG vaccination during childhood had no protective effect on getting COVID-19 infection later. 2) Bladder cancer pts on BCG therapy who get COVID infection, can safely take IL-6 or IL-1 inhibitors, Just not TNF inhib.
The EXCEED study was a head-to-head trial of secukinumab (SEC) versus adalimumab (ADA) as first-line monotherapy in psoriatic arthritis (PsA) patients; this 52 week trial showed that while SEC failed to achieve clinical superiority over ADA, SEC treated patients demonstrated higherRead Article
Many patients with rheumatoid arthritis (RA) who achieved remission or low disease activity on biologic treatment were able to reduce the dose of their biologic, particularly if they were also on methotrexate, a retrospective study found.Read Article
The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic.
These preliminary recommendations are based on an expert consensus from 17
Arthritis & Rheumatology reports that biologic (bDMARD) use in rheumatoid arthritis may decrease cardiovascular disease risk by retarding coronary plaque formation and progression (especially non‐calcified and low‐attenuation plaque).Read Article
Patients with rheumatoid arthritis (RA) treated with abatacept (Orencia) had a lower risk of developing diabetes mellitus compared with those receiving certain tumor necrosis factor (TNF) inhibitors, a large cohort study suggested.Read Article
Dr. Jack Cush reviews the appproach to evaluating fever in adults suspected of having a rheumatic disease, Stills disease or autoinflammatory conditions. Presentations, fever duration, disease criteria and genetic testing are discussed.Read Article
On April 11th, the ACR Board of Directors approved a COVID-19 guidance document written by an ACR task force charged with updating and clarifying recommendations for rheumatologists and rheumatic disease patient management during the current COVID-19 crisis.
This ACR release, in itsRead Article
The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.Read Article
On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.Read Article